Led · Equity · Nov 2021

HealthSnap offers an enterprise-grade, EMR-integrated virtual care management platform that combines RPM, CCM, PCM, APCM, AI-augmented clinical workflows, enterprise analytics, reimbursement optimization, and care coordination. The company has embedded AI across care delivery to produce clinician-facing recommendations within clinician-defined protocols and safety guardrails, and launched an AI-augmented APCM solution earlier in the year. HealthSnap supports more than 80,000 active patient programs across 200 health systems and physician organizations, and projects more than 100,000 active patient programs by the end of 2026. Its platform ingests roughly two patient measurements every second, and patients see a 97% reduction in alert frequency by their twelfth month. The company reported significant commercial momentum and financial improvement, including more than fivefold revenue growth over three years, 40% year-over-year revenue growth, and a 47% year-over-year improvement in EBITDA. HealthSnap’s clinical research has shown measurable outcomes, including an average 7.3 mmHg reduction in systolic blood pressure across a cohort of more than 6,500 patients (rising to 16.7 mmHg for Stage 2 hypertensive patients) and retrospective findings of material reductions in total cost of care, hospitalizations, and ED visits among high-acuity Medicare beneficiaries.

Led · Series C · Jun 2017

Eloxx Pharmaceuticals is focused on ELX-02, an investigational drug designed to bypass premature stop signals caused by nonsense mutations in the CFTR gene and restore production of full-length, functional CFTR protein. Laboratory data cited in the announcement indicate that combining ELX-02 with CFTR modulators could increase read-through activity by several fold. The company's ongoing clinical program is being expanded to test ELX-02 in combination with the CFTR modulator ivacaftor (Kalydeco®); that expanded study is already enrolling and expects results by mid-2022. The clinical expansion is supported by the Cystic Fibrosis Foundation, which previously provided up to $3.6 million for Eloxx’s initial ELX-02 studies and has now awarded up to $15.9 million in additional funding. The award provides both financial and scientific support and is part of the Foundation’s $500 million Path to a Cure initiative. No company revenue or user metrics are disclosed in the article. Eloxx Pharmaceuticals announced it has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. The company has drawn an initial tranche of $12.5 million. Proceeds from the initial draw were used to repay in full amounts outstanding under Eloxx’s existing debt facility. The remaining funds under the new facility will be available in additional tranches upon the achievement of specific clinical milestones or other terms and conditions. The arrangement gives Eloxx access to up to $30.0 million of debt capital contingent on clinical and contractual triggers. The announcement did not disclose any equity financings, revenue figures, or user metrics. Eloxx Pharmaceuticals is a clinical-stage biotech developing ELX-02, a designer aminoglycoside translation read-through inducing drug (TRID) targeting genetic diseases caused by nonsense mutations. ELX-02 has completed comprehensive preclinical testing and a monocentric Phase 1a single-ascending-dose (SAD) study in healthy volunteers. The company plans a Phase 1b multiple-ascending-dose (MAD) study and Phase 2 trials in cystic fibrosis and cystinosis patients carrying nonsense mutations, and intends to test additional indications. Nonclinical models demonstrating ELX-02 activity include CF, cystinosis, Duchenne muscular dystrophy, Rett syndrome and MPS I. Eloxx completed a toxicology program in accordance with ICH M3 (R2) to support its clinical studies. The company announced plans tied to an acquisition transaction with Sevion that could affect its corporate structure and public-listing plans.

Led · Equity · Apr 2015

MabVax is focused on developing vaccine and antibody-based therapies to address unmet needs in cancer treatment. Its lead program, HuMab 5B1, is being developed as both a diagnostic and therapeutic targeting pancreatic and colon cancer. The company reports a pipeline of dozens of novel antibody leads from its discovery platform. MabVax has licensing relationships with Memorial Sloan Kettering Cancer Center and Juno Therapeutics. The San Diego–based firm said the recent financing will fund initiation of Phase 1 human clinical trials for HuMab 5B1 later in the year and support additional preclinical research programs. The deal also brought endorsement from billionaire investor Dr. Phillip Frost and OPKO Health. MabVax Therapeutics is a San Diego-based biotechnology company developing vaccine-based treatments for cancer. The company is developing a pancreatic cancer treatment that the newly awarded NIH grant will help fund. The award is a $1.75 million grant from the National Institutes of Health as part of the Small Business Innovation Research (SBIR) Technology Program. Founded in March 2008, MabVax has raised $12 million in venture funding and $6 million in NIH funding to date, according to CEO David Hansen. The company is a small private firm focused on translating cancer vaccines into clinical programs. MabVax Therapeutics is a San Diego-based clinical-stage biotechnology company developing proprietary immunotherapies. Its lead programs include a phase 2 vaccine aimed at preventing recurrent sarcoma and a 5B1 antibody program targeting metastatic pancreatic cancer. Derivatives of the 5B1 antibody are being developed as a radiolabeled imaging agent to improve diagnosis, staging, and treatment assessment of pancreatic cancer. The company plans to begin GMP manufacturing of the 5B1 antibody early in 2013 and intends to enter phase 1 clinical trials in 2014. MabVax recently closed the first tranche of a $5.25M Series B financing, which it will use to continue development and manufacturing activities. Existing investors Burrill Capital Fund IV and RTP Venture Fund participated in the tranche.

Participated · Equity · Nov 2010

Fabrus, LLC is a La Jolla, CA-based early-stage biotechnology company focused on discovering and developing antibody therapeutics. The company’s core work centers on identifying and developing antibody drug candidates. Fabrus recently secured external financing to advance its pipeline. Investors in the financing include OPKO Health, Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. As part of the transaction, Phillip Frost, M.D., OPKO, and Jane Hsiao, Vice Chairman and CTO of OPKO, joined Fabrus’ Board of Managers. The funds will be used to develop drug candidates.